Approaches for Systemic Delivery of Dystrophin Antisense Peptide Nucleic Acid in the mdx Mouse Model
June 4, 2021
June 4, 2021
Videoconference and publication of the results for the 2020-2021 financial year, on June 16, 2021
June 1, 2021
June 1, 2021
Poly(ethylene glycol)-b-poly(1,3-trimethylene carbonate) Copolymers for the Formulation of In Situ Forming Depot Long-Acting Injectables
April 22, 2021
April 22, 2021
Clinical trial conducted by MedinCell confirms the safety of continuous administration of ivermectin
April 19, 2021
April 19, 2021
MedinCell: mdc-CWM clinical phase 3 will start in 2021
March 25, 2021
March 25, 2021
Poly(ethylene glycol)-b-poly(1,3-trimethylene carbonate) Amphiphilic Copolymers for Long-Acting Injectables: Synthesis, Non-Acylating Performance and In Vivo Degradation
March 6, 2021
March 6, 2021
Covid-19: MedinCell publishes an extensive Ivermectin Safety Expert Analysis
March 5, 2021
March 5, 2021
Expert Review Report: Medical Safety of Ivermectin
March 3, 2021
March 3, 2021
Tremendous success for MedinCell’s €30 million capital increase for qualified investors
February 11, 2021
February 11, 2021
MedinCell announces a capital increase of a c.€30 million
February 10, 2021
February 10, 2021
MedinCell announces three new products entering regulatory development
February 2, 2021
February 2, 2021
Contacts
Medincell
David Heuzé
Head of Corporate and Financial Communications, and ESG
